(adherent), $12,619 (partially adherent) and $8,675 (non-adherent). The adherent class had a lower average cost than the nonadherent class in all the cost categories but drug costs were $1,939 higher (all p-values <0.05). CONCLUSION: Multiple indicators of adherence to antipsychotic medication capture heterogeneity in non-adherence behaviors, which can be modeled using latent classes, so define non-adherence casemix. OBJECTIVE: To determine the relationship between ziprasidone starting dose and persistence among patients diagnosed with schizophrenia. METHODS: Adult Medicaid recipients diagnosed with schizophrenia and having ziprasidone prescription claims between July 1, 2001 and September 30, 2003 were categorized by starting dosage: low (20-60 mg) n = 517; medium (61 mg-119 mg) n = 339; and high (120-160 mg) n = 341. Persistence was measured using refill patterns, allowing 15-day gaps between expected refill dates, and compared across starting doses using Chi-Square tests. Multivariate logistic analysis explored the simultaneous impact of age, gender, race, and year of treatment initiation in addition to starting dose. RESULTS: Discontinuation rates across the study period (maximum 30 months) were greater for patients initiated with low (p = 0.001) and medium dose (p = 0.02) than for high dose patients. Discontinuation rates were not statistically different for low and medium doses. Discontinuation rates at 365, 180, and 90 days were higher for low dose than high dose (p < 0.05) but not significantly different between low and medium or medium and high doses. These results were similar in the multivariate models. CONCLUSIONS: Schizophrenia patients started on high doses of ziprasidone have greater persistence up to 2 1 / 2 years than those who start on low doses. OBJECTIVES: The primary objective compared antipsychotic non-adherence rates of outpatients with schizophrenia or schizoaffective disorder as assessed by electronic monitoring vs. prescriber ratings. Secondary objectives evaluated the relationship between electronically-determined antipsychotic adherence with (1) various baseline patient characteristics and (2) prospectively assessed symptom severity, quality of life (QoL) and cognition. METHODS: Adult outpatients with schizophrenia or schizoaffective DSM-IV diagnosis, taking a single oral antipsychotic, and who signed informed consent were eligible. Adherence was measured via electronic-monitored medication vial caps, prescriber report, patient self-report and research assistant report, at baseline and monthly for up to six-months, as were symptom severity (PANSS) and QoL (SQLS, LOF, PSP). Patients were non-adherent if adherence was <70% for two or more months during the six-month study. A single cognition assessment (BACS) was performed. RESULTS: Sixty-one patients (mean age 44.3, b9.1 years, 51% female, illness duration 21.2, b 10.7 years) were included. Antipsychotic non-adherence detection was significantly higher with electronic monitoring (57%) vs. prescriber assessment (7%; p < 0.0001, N = 60) and vs. patient self-assessment (5%; p < 0.0001), but was not different from research assistant assessment (54%; p < 0.67). While the total number of patients classified as adherent and non-adherent by research assistants and electronic monitoring were similar, disagreement in assignment occurred in 36% of cases. Poorer mean adherence was associated with baseline characteristics of less than high school education (p < 0.0001), non-Caucasian race (p = 0.001), and more severe symptoms (p = 0.001). Lower mean adherence rates were also associated with worse mean six-month symptom (PANSS total; p < 0.002) and lower functioning on one of three QoL scales (SQLS; p < 0.03) ratings. No relationship was found between adherence and cognition. CONCLUSION: In patients with schizophrenia and schizoaffective disorder, nonadherence is significantly underestimated/underreported by prescribers and patients. Results suggest non-adherence with antipsychotic medication therapy is associated with worse symptoms, poorer QoL, less than high school education and non-Caucasian race. OBJECTIVES: To evaluate long-term clinical and economic outcomes in patients participating in the ongoing Electronic Schizophrenia Treatment Adherence Registry in Germany, who were initiated on long-acting injectable risperidone (LAIR). Baseline and retrospective data will be presented. METHODS: Data are collected via a secured web-based system for 12 months retrospectively and for 2 years prospectively. Data collected include patient demographics, treatment and hospitalisation history, reason for initiating new antipsychotic treatment, Clinical Global Impression-Severity (CGI-S), Global Assessment of Functioning (GAF) and adverse events. RESULTS: Complete baseline and retrospective data are available for 744 patients. Mean (±SD) age is 41.0 years (±12.2), 56% of patients are male, and 97% have a diagnosis of schizophrenia or schizoaffective disorder. The mean (±SD) duration of illness at the time of LAIR initiation is 9.2 (±9.1) years. Eighty-six percent of patients had a CGI-S score of moderate (30.5%), marked (35.5%) or severe (20.3%). The mean (±SD) GAF score was 46 (±15). Seventy-two percent of patients had at least one hospitalisation during the year before LAIR initiation; 39% patients received oral atypicals, 5% oral conventionals, 15% depot conventionals, and 31% received different types of antipsychotics simultaneously or sequentially in the year preceding LAIR initiation. For 10% of patients, no retrospective medication information was indicated. The most frequent reasons for LAIR initiation were lack of compliance (37%), insufficient response (27%), and unacceptable tolerability (16%) with the previous medication(s). Fifty-three percent of patients started on 25 mg/14 days of long-acting risperidone, 31% on 37.5 mg/14 days and 16% on 50 mg/14 days. CONCLUSIONS: Patients in this sample demonstrate distinct symptomatology and impairment in functioning. Despite a considerable proportion of patients previously treated with novel
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Mullins CD 1 , Shaya FT 2 , Zito J 2 , Gardner J 2 , McNally D 2 , Meng F 2 , Harrison D 3 1 Pharmaceutical Health Services Research, Baltimore, MD, USA; 2 University of Maryland, Baltimore, MD, USA; 3 Pfizer Inc, New York, NY, USA OBJECTIVE: To determine the relationship between ziprasidone starting dose and persistence among patients diagnosed with schizophrenia. METHODS: Adult Medicaid recipients diagnosed with schizophrenia and having ziprasidone prescription claims between July 1, 2001 and September 30, 2003 were categorized by starting dosage: low (20-60 mg) n = 517; medium (61 mg-119 mg) n = 339; and high (120-160 mg) n = 341. Persistence was measured using refill patterns, allowing 15-day gaps between expected refill dates, and compared across starting doses using Chi-Square tests. Multivariate logistic analysis explored the simultaneous impact of age, gender, race, and year of treatment initiation in addition to starting dose. RESULTS: Discontinuation rates across the study period (maximum 30 months) were greater for patients initiated with low (p = 0.001) and medium dose (p = 0.02) than for high dose patients. Discontinuation rates were not statistically different for low and medium doses. Discontinuation rates at 365, 180, and 90 days were higher for low dose than high dose (p < 0.05) but not significantly different between low and medium or medium and high doses. These results were similar in the multivariate models. CONCLUSIONS: Schizophrenia patients started on high doses of ziprasidone have greater persistence up to 2 1 / 2 years than those who start on low doses.
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Byerly M 1 , Thompson A 2 , Carmody T 1 , Erwin T 1 , Bugno R 1 , Rush J 1 1 University of Texas Southwestern, Dallas, TX, USA; 2 Janssen Medical Affairs, LLC, Leawood, KS, USA OBJECTIVES: The primary objective compared antipsychotic non-adherence rates of outpatients with schizophrenia or schizoaffective disorder as assessed by electronic monitoring vs. prescriber ratings. Secondary objectives evaluated the relationship between electronically-determined antipsychotic adherence with (1) various baseline patient characteristics and (2) prospectively assessed symptom severity, quality of life (QoL) and cognition. METHODS: Adult outpatients with schizophrenia or schizoaffective DSM-IV diagnosis, taking a single oral antipsychotic, and who signed informed consent were eligible. Adherence was measured via electronic-monitored medication vial caps, prescriber report, patient self-report and research assistant report, at baseline and monthly for up to six-months, as were symptom severity (PANSS) and QoL (SQLS, LOF, PSP). Patients were non-adherent if adherence was <70% for two or more months during the six-month study. A single cognition assessment (BACS) was performed. RESULTS: Sixty-one patients (mean age 44.3, b9.1 years, 51% female, illness duration 21.2, b 10.7 years) were included. Antipsychotic non-adherence detection was significantly higher with electronic monitoring (57%) vs. prescriber assessment (7%; p < 0.0001, N = 60) and vs. patient self-assessment (5%; p < 0.0001), but was not different from research assistant assessment (54%; p < 0.67). While the total number of patients classified as adherent and non-adherent by research assistants and electronic monitoring were similar, disagreement in assignment occurred in 36% of cases. Poorer mean adherence was associated with baseline characteristics of less than high school education (p < 0.0001), non-Caucasian race (p = 0.001), and more severe symptoms (p = 0.001). Lower mean adherence rates were also associated with worse mean six-month symptom (PANSS total; p < 0.002) and lower functioning on one of three QoL scales (SQLS; p < 0.03) ratings. No relationship was found between adherence and cognition. CONCLUSION: In patients with schizophrenia and schizoaffective disorder, nonadherence is significantly underestimated/underreported by prescribers and patients. Results suggest non-adherence with antipsychotic medication therapy is associated with worse symptoms, poorer QoL, less than high school education and non-Caucasian race.
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Naber D 1 , Mehnert A 2 , Rosillon D 3 , Farmer D 4 , Schreiner A 2 , Jacobs A 5 1 University Hospital Hamburg-Eppendorf, Hamburg, Germany; 2 Janssen-Cilag GmbH, Neuss, Germany; 3 SGS Biopharma, Wavre, Belgium; 4 Interactive Educational Systems, Ltd, Hampton Court, Surrey, UK; 5 Janssen Pharmaceutica, Beerse, Belgium OBJECTIVES: To evaluate long-term clinical and economic outcomes in patients participating in the ongoing Electronic Schizophrenia Treatment Adherence Registry in Germany, who were initiated on long-acting injectable risperidone (LAIR). Baseline and retrospective data will be presented. METHODS: Data are collected via a secured web-based system for 12 months retrospectively and for 2 years prospectively. Data collected include patient demographics, treatment and hospitalisation history, reason for initiating new antipsychotic treatment, Clinical Global Impression-Severity (CGI-S), Global Assessment of Functioning (GAF) and adverse events. RESULTS: Complete baseline and retrospective data are available for 744 patients. Mean (±SD) age is 41.0 years (±12.2), 56% of patients are male, and 97% have a diagnosis of schizophrenia or schizoaffective disorder. The mean (±SD) duration of illness at the time of LAIR initiation is 9.2 (±9.1) years. Eighty-six percent of patients had a CGI-S score of moderate (30.5%), marked (35.5%) or severe (20.3%). The mean (±SD) GAF score was 46 (±15). Seventy-two percent of patients had at least one hospitalisation during the year before LAIR initiation; 39% patients received oral atypicals, 5% oral conventionals, 15% depot conventionals, and 31% received different types of antipsychotics simultaneously or sequentially in the year preceding LAIR initiation. For 10% of patients, no retrospective medication information was indicated. The most frequent reasons for LAIR initiation were lack of compliance (37%), insufficient response (27%), and unacceptable tolerability (16%) with the previous medication(s). Fifty-three percent of patients started on 25 mg/14 days of long-acting risperidone, 31% on 37.5 mg/14 days and 16% on 50 mg/14 days. CONCLUSIONS: Patients in this sample demonstrate distinct symptomatology and impairment in functioning. Despite a considerable proportion of patients previously treated with novel
